Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...

Boston Scientific (NYSE: BSX) + today reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance again. The company’s CEO also said on its third ...

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. Now, it has resumed its work to see whether its Farapulse platform can ...

The Farapulse Farawave catheter and Faraview software. [Image courtesy of Boston Scientific] Boston Scientific (NYSE: BSX) + announced today that it received FDA approval for its navigation ...

Boston Scientific is launching the Farawave Nav ablation catheter and Faraview software to treat atrial fibrillation in the U.S. · MedTech Dive · Courtesy of Boston Scientific Boston Scientific ...

Credit: Sundry Photography via Shutterstock. Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a few unanticipated observations” ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...